GLP-1 Weight Loss: How Can People Maintain Results?

Can structured support limit weight regain after stopping GLP-1s?

Researchers randomly assigned adults who had stopped GLP-1 treatment to usual care, a behavioral app or dietitian-designed meal deliveries. Estimated weight gain over follow-up was approximately 3.6% in either support group versus 10.8% with usual care, measured relative to weight at study entry. All groups regained weight on average. [Pilot trial](https://onlinelibrary.wiley.com/doi/10.1002/osp4.70194).

Weight was an exploratory outcome; the main measures concerned adherence and satisfaction. The small, predominantly female sample and brief follow-up limit confidence in effectiveness across populations. The findings do not establish equivalence to continued medication. Public and university grants funded the study; the lead author disclosed subsequent Noom funding for a larger trial. These results justify further testing, rather than a recommendation to replace medication with an app or meal service. [Study methods and disclosures](https://onlinelibrary.wiley.com/doi/10.1002/osp4.70194).

What happens to weight when GLP-1 treatment stops?

The STEP 1 extension followed a subset of participants after semaglutide 2.4 mg and the trial's lifestyle intervention ended. Within one year, participants previously receiving semaglutide regained approximately two-thirds of their earlier weight loss, on average. Several improvements in cardiovascular and metabolic risk factors also moved back toward baseline. Because both medication and structured lifestyle support stopped, the extension cannot isolate their separate contributions to regain. [STEP 1 extension](https://pubmed.ncbi.nlm.nih.gov/35441470/).

SURMOUNT-4 provides randomized evidence about continued medication. After an initial tirzepatide treatment period, 670 adults without diabetes continued treatment or switched to placebo while receiving lifestyle guidance. Over the next 52 weeks, weight decreased another 5.5% with continued treatment and increased 14.0% with placebo, relative to weight at randomization. Tirzepatide acts on both GIP and GLP-1 receptors. The manufacturer-funded trial supports ongoing treatment for suitable patients, although its selected population and follow-up duration limit predictions for any individual. [SURMOUNT-4 trial](https://jamanetwork.com/journals/jama/fullarticle/2812936).

How should people plan for long-term weight maintenance?

The National Institute of Diabetes and Digestive and Kidney Diseases describes obesity as a chronic condition and notes that effective, tolerated medication may be continued indefinitely. Reaching a target weight is therefore a reason to review treatment goals with the prescriber. That discussion should consider benefits, side effects, other health conditions and affordability. GLP-1 medicines influence appetite regulation; stopping them removes that ongoing treatment effect. Any change in medication or dosing should follow an agreed clinical plan. [NIDDK medication guidance](https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity).

A practical maintenance program includes an eating plan suited to the person's current needs, achievable activity goals and regular feedback. NIDDK recommends support for monitoring habits and weight, with counseling that helps people address barriers and setbacks. For online programs, access to qualified professionals and individualized feedback matters more than tracking features alone. Exercise also provides health benefits independent of weight change. The practical implication is to arrange follow-up and support before treatment changes, with a clear route back to the care team if maintaining progress becomes difficult. [NIDDK program guidance](https://www.niddk.nih.gov/health-information/weight-management/choosing-a-safe-successful-weight-loss-program).